ctrl K

AI Score

Unlock

Lyell Immunopharma Inc. (LYEL)

AI Score

Unlock

0.66

-0.05 (-7.15%)

At close: Mar 03, 2025, 12:36 PM

Lyell Immunopharma Income Statement

Table Mode

Year	FY23	FY22	FY21	FY20	FY19
Revenue	130K	84.68M	10.65M	7.76M	657K
Cost of Revenue	n/a	16.47M	14.54M	7.47M	n/a
Gross Profit	130K	68.22M	-3.88M	281K	657K
Operating Income	-247.01M	-183.12M	-214.78M	-211.94M	-102.09M
Interest Income	23.45M	7.05M	1.17M	5.94M	8.12M
Pretax Income	-234.63M	-183.12M	-250.22M	-204.47M	-129.38M
Net Income	-234.63M	-4.75M	-285.5M	-198.53M	-121.26M
Selling & General & Admin	66.98M	117.31M	89.06M	46.88M	39.15M
Research & Development	182.94M	159.19M	138.69M	182.24M	63.59M
Other Expenses	-2.79M	1.89M	-2.32M	-9.43M	-35.41M
Operating Expenses	247.14M	276.5M	225.43M	219.69M	102.75M
Interest Expense	n/a	n/a	n/a	n/a	n/a
Selling & Marketing Expenses	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	247.14M	276.5M	225.43M	219.69M	102.75M
Income Tax	n/a	-178.36M	35.28M	-5.94M	-8.12M
Shares Outstanding (Basic)	250.98M	247.08M	242.74M	246.58M	246.58M
Shares Outstanding (Diluted)	250.98M	247.08M	242.74M	246.58M	246.58M
EPS (Basic)	-0.93	-0.02	-1.18	-0.81	-0.49
EPS (Diluted)	-0.93	-0.02	-1.18	-0.81	-0.49
EBITDA	-226.76M	-166.65M	-199.94M	-207.64M	-100.83M
Depreciation & Amortization	20.25M	16.47M	14.54M	7.47M	4.38M